K4 Elite logo K4 Elite
Home / Peptide Library / Cardiogen
Limited Research

Cardiogen

Cardiovascular Health · ['Cardiogen peptide bioregulator', 'Ala-Glu-Asp-Arg (related peptide)', 'Cardiac peptide complex']

Cardiogen is a peptide bioregulator associated with cardiac-tissue research in the Khavinson short-peptide tradition, studied in preclinical and clinical-report settings for cardiovascular endpoints.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Research Level
Limited Research
Browse the store →
🧬

Cardiogen is described in the source literature as a peptide bioregulator connected to cardiac tissue. Some commercial preparations are characterized as tissue-derived peptide complexes, while related research references a short synthetic peptide (for example an Ala-Glu-Asp-Arg motif) studied in the same bioregulator tradition. Because catalog preparations are typically mixtures, no single molecular formula or PubChem identifier is assigned here.

It falls within the family of short peptide bioregulators developed and studied largely by Russian researchers, who describe these peptides as tissue-specific regulators intended in their model to influence gene expression and cellular function in the corresponding organ—here, cardiovascular tissue.

The body of research is comparatively limited and concentrated in regional journals, so Cardiogen is best regarded as a compound of emerging and limited scientific characterization.

The proposed mechanism in the peptide-bioregulator literature holds that short peptides such as those in the Cardiogen family can interact with regulatory regions of DNA or with signaling pathways in a tissue-specific manner, thereby modulating the expression of genes relevant to cardiac and vascular cells. This model is described by its proponents as epigenetic-style regulation.

Experimental reports associate the cardiac peptide fraction with modulation of markers of cardiomyocyte function and vascular tone in laboratory models, though the molecular targets are not as thoroughly characterized as for well-studied single-molecule compounds.

  • Cardiac-tissue-specific gene-expression modulation in the bioregulator model
  • Cardiomyocyte function markers in preclinical studies
  • Vascular tone and endothelial endpoints in experimental models
  • Age-related cardiovascular decline in short-peptide research
  • Comparative studies within the Khavinson peptide-bioregulator family
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Khavinson and colleagues, in reviews of short peptide bioregulators (e.g., Biogerontology and Bulletin of Experimental Biology and Medicine), describe tissue-specific peptides being evaluated in cell cultures and animal models for effects on organ-specific gene expression and function, reporting altered expression of tissue markers relative to controls in the cited experiments.

Regional clinical-report literature describes cardiac peptide preparations being assessed in patient cohorts with cardiovascular endpoints, summarizing changes in functional or laboratory measures. These are experimental and clinical-report exposures in the source region and are not use recommendations for this catalog.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Other Khavinson bioregulators (e.g., Vesugen, Vladonix)Neutral
Studied within the same tissue-specific short-peptide bioregulator family with distinct organ targets.
Cardiac gene-expression pathwaysCompatible
The bioregulator model proposes tissue-specific modulation of cardiac gene expression.
Vascular signalingCompatible
Reports associate the peptide fraction with vascular-tone and endothelial markers in models.
Antioxidant systemsSynergistic
Some source-literature reports describe reduced oxidative-stress markers in cardiac tissue models.

References are being compiled for this entry.

What is Cardiogen?
Cardiogen is a cardiac-associated peptide bioregulator studied within the Russian short-peptide research tradition for cardiovascular-tissue endpoints.
Why is there no molecular formula listed?
Catalog preparations are typically tissue-derived peptide mixtures rather than a single defined molecule, so no single molecular formula or PubChem CID is assigned.
What is the proposed mechanism of peptide bioregulators?
Their proponents describe short peptides interacting with DNA regulatory regions in a tissue-specific way to modulate gene expression; this remains a research model.
How strong is the evidence for Cardiogen?
The research base is limited and concentrated in regional journals, so it is characterized here as a compound with limited scientific characterization.
Can I use Cardiogen for my heart health?
No. This material is provided strictly for research-use-only and is not intended to diagnose, treat, cure, or prevent any condition in humans or animals.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.